GenoMed Inc. (GMED)

[mingwan0]

The PR was again picked up by News-Medical.Net:

http://www.news-medical.net/view_article.asp?id=1679

This is the same text as the PR. There is also an article in the St Louis Business Journal:

http://stlouis.bizjournals.com/stlouis/stories/2004/05/17/daily38.html?jst=b_ln_hl

GenoMed inks genotyping deal with Genome Quebec McGill University and the Genome Quebec Innovation Centre in Montreal will provide genotyping services for St. Louis-based GenoMed under a new deal announced Wednesday.

Financial terms were not disclosed.

The Genome Quebec Innovation Centre's Illumina genotyping solution allows for the screening of a large number of single nucleotide polymorphisms, or SNPs, which are DNA sequence variations that occur when one nucleotide in the genome sequence is altered. Scientists believe SNP maps will help them identify the multiple genes associated with such complex diseases as cancer, diabetes, vascular disease and some forms of mental illness, according to the Human Genome Project's Web site.

Genome Quebec supports researchers from academic, industrial and government settings and manages a portfolio worth about $220 million.

St. Louis-based GenoMed Inc. (Pink Sheets: GMED) is a medical genomics company working to find genes that cause disease.

End of article

As I noted before:

http://www.investorshub.com/boards/read_msg.asp?message_id=3080492

GMED have earmarked $800,000 for genotyping over the next 12 months, and an unknown percentage of this amount will be devoted to "screening" rather than "validation genotyping". Perhaps we will get some details of the agreement in the 10Q.